Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Varenicline Tartarate · 1 trial · 1 indication
Number of subjects who reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory \[NUI\]) and with end-expiratory exhaled carbon monoxide (CO) measurement less than or equal to 10 parts per million (ppm) for weeks 9 through 12 (inclusive).
| Arm | Type | Description |
|---|---|---|
| placebo | PLACEBO_COMPARATOR | - |
| varenicline | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| placebo | DRUG | 1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days) |
| Varenicline Tartarate | DRUG | 1 mg by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days) |
Inclusion Criteria: * Subjects will be current cigarette smokers who have smoked an average of at least 10 cigarettes per day during the past year and during the month prior to the screening visit. * mild to moderate COPD confirmed by spirometry * Subjects must have a clinical diagnosis of COPD. E...
Varenicline Tartarate is used for smoking cessation. It is being developed as a treatment to help people stop smoking, specifically studied in subjects with mild-to-moderate chronic obstructive pulmonary disease (COPD). The drug is a small molecule in the psychiatry therapeutic area.
Varenicline Tartarate is being developed by Pfizer, Inc., a company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical development for smoking cessation.
Varenicline Tartarate is in Phase 3 clinical development. It is an investigational drug for smoking cessation and has not been approved by regulatory authorities. The Phase 3 trial has been completed.
Varenicline Tartarate has one completed Phase 3 clinical trial with the identifier NCT00285012. The trial, titled "Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)," enrolled 504 participants across the United States, France, Italy, and Spain.
Varenicline Tartarate is a salt form of varenicline, a medication used for smoking cessation. The drug is being developed by Pfizer, Inc. and has been studied in a Phase 3 trial for smoking cessation in patients with mild-to-moderate COPD.